KR20000007943A - Whitening cosmetic containing extracts from a bamboo endothelium - Google Patents

Whitening cosmetic containing extracts from a bamboo endothelium Download PDF

Info

Publication number
KR20000007943A
KR20000007943A KR1019980027529A KR19980027529A KR20000007943A KR 20000007943 A KR20000007943 A KR 20000007943A KR 1019980027529 A KR1019980027529 A KR 1019980027529A KR 19980027529 A KR19980027529 A KR 19980027529A KR 20000007943 A KR20000007943 A KR 20000007943A
Authority
KR
South Korea
Prior art keywords
bamboo
extract
whitening
endothelium
skin
Prior art date
Application number
KR1019980027529A
Other languages
Korean (ko)
Other versions
KR100357402B1 (en
Inventor
조준환
이기무
공우식
서충석
강원형
이성낙
Original Assignee
안용찬
애경산업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안용찬, 애경산업 주식회사 filed Critical 안용찬
Priority to KR10-1998-0027529A priority Critical patent/KR100357402B1/en
Publication of KR20000007943A publication Critical patent/KR20000007943A/en
Application granted granted Critical
Publication of KR100357402B1 publication Critical patent/KR100357402B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

PURPOSE: A whitening cosmetic containing an extract from the endothelium of Phyllostachys pubescens MAZEL is provided, which shows excellent whitening effect without skin irritation and gets over the problem like as an eye-sight change during manufacturing and keeping of product. CONSTITUTION: The whitening cosmetic contains 0.0001¯5%, desirably 0.001¯3% of the dried bamboo endothelium on the basis of total cosmetic weight. The bamboo endothelium is gained as a by-product from a process of producing the 2nd layer skin using in bamboo works. The next extraction process comprises of: crushing to pieces after drying; extracting with a solution mixed as 8:2 of ethanol or methanol and waters, or ethanol or methanol individually; keeping this for 1¯15 days at 15¯37 C; concentrating this extract under the decompression using a distiller eqiupped with a cooling condenser; and drying.

Description

죽내피 추출물을 함유한 미백화장료Whitening cosmetics containing bamboo extract

본 발명은 미백화장료에 관한 것으로 더욱 상세하게는 미백 유효성분으로서 대나무(Phyllostachys pubescens MAZEL)의 속내피로부터 추출된 죽내피 추출물을 함유하고 있는 미백화장료에 관한 것이다.The present invention relates to a whitening cosmetics, and more particularly to a whitening cosmetics containing bamboo endothelial extract extracted from the inner endothelium of bamboo (Phyllostachys pubescens MAZEL) as a whitening active ingredient.

사람의 피부색은 주로 피부세포속에 함유되어 있는 멜라닌 색소의 양에 따라 크게 좌우된다. 멜라닌 색소가 많은 사람은 갈색 또는 검은 색 피부를 갖는 반면, 멜라닌 색소가 극히 적은 사람은 백반증의 원인이 된다. 멜라닌 색소는 피부의 기저막에 존재하는 멜라노사이트라는 색소세포에서 티로시나아제에 의해 티로신으로부터 생성된다.Human skin color depends largely on the amount of melanin pigment contained in skin cells. People with high levels of melanin have brown or black skin, while people with very low levels of melanin cause vitiligo. Melanin pigment is produced from tyrosine by tyrosinase in pigment cells called melanocytes, which are present in the basal membrane of the skin.

멜라닌 색소는 과도한 자외선으로부터 피부를 보호함으로써 광선에 의한 피부손상, 피부암의 발생을 억제하는 중요한 역할을 한다. 그러나 일광, 호르몬변화, 염증, 약제 등에 의해 멜라닌이 과다하게 생성되는 경우 피부의 색소가 침착되며, 이로 인해 미용상 여러 가지 문제를 야기한다. 예를 들어, 피부의 과색소 질환인 기미나 주근깨 등은 멜라닌 색소의 양이 증가한 것에 기인한 것으로, 이는 멜라닌 색소의 생성과정이 촉진되거나 멜라닌 세포의 수가 증가하였다는 것을 의미한다.Melanin pigments play an important role in protecting the skin from excessive ultraviolet rays, thereby preventing skin damage and the occurrence of skin cancer. However, excessive production of melanin due to sunlight, hormonal changes, inflammation, drugs, etc. deposits skin pigments, which causes a variety of cosmetic problems. For example, skin pigmentation, freckles, and freckles are caused by an increase in the amount of melanin pigment, which means that the production of melanin pigment is promoted or the number of melanocytes is increased.

현재 피부미용을 위한 미백제의 개발에 있어서, 생성된 멜라닌 색소를 환원시켜 탈색하는 방법과 멜라닌 색소를 형성하는 효소인 티로시나제의 활성을 억제하는 방법이 알려져 있다. 그러나 멜라닌 색소를 환원시키기 위해 사용되는 토코페롤이나 비타민류등을 사용한 미백제는 멜라닌 색소의 탈색효과가 미미한 것으로 알려져 있다. 따라서 티로시나제의 활성을 저해시킴으로써 멜라닌 색소의 생성을 억제하는 저해제가 주목받고 있다.At present, in the development of a whitening agent for skin beauty, a method of reducing the generated melanin pigment by decolorization and a method of inhibiting the activity of tyrosinase, an enzyme that forms melanin pigment, are known. However, whitening agents using tocopherols or vitamins, which are used to reduce the melanin pigment, are known to have a slight decolorizing effect of the melanin pigment. Therefore, attention is being paid to inhibitors that inhibit the production of melanin by inhibiting the activity of tyrosinase.

티로시나아제는 모노페놀류를 산화하는 반응을 촉매하는 효소로 고등동물의 멜라닌 세포 속에 들어있다. 이 효소에 의해 티로신은 도파퀴논으로 산화되어 일련의 화학반응, 산화 등을 거쳐 멜라닌 색소가 생성되게 된다. 이 멜라닌 색소는 갈색이나 흑색을 띠는 것으로 생체 내에서 과량의 빛을 흡수하게 하여 피부미용에 나쁜 영향을 미치게 된다.Tyrosinase is an enzyme that catalyzes the reaction of oxidizing monophenols into melanocytes of higher animals. By this enzyme, tyrosine is oxidized to dopaquinone, and melanin pigment is produced through a series of chemical reactions and oxidation. This melanin pigment is brown or black, which absorbs excessive light in vivo and thus adversely affects skin beauty.

미백제 선별에 있어서, 현재 널리 사용되고 있는 방법은 버섯으로부터 정제된 티로시나제를 이용하여 티로시나제의 활성을 저해시키는 저해제를 선택하는 방법과 쥐의 흑색종 세포를 이용하여 미백원에 대한 흑색종 세포의 상태를 평가하여 선택하는 방법이 있다. 전자는 간편하고 시간, 비용 등이 절약되는 장점이 있으나 단지 티로시나제 저해제만을 선별할 수 있다는 단점이 있고, 후자는 좀더 종합적으로 미백제를 선별할 수 있으나 비용, 시간, 노력 등이 많이 소비된다는 단점이 있다.In the selection of whitening agents, currently widely used methods are to select inhibitors that inhibit tyrosinase activity using tyrosinase purified from mushrooms and to evaluate the status of melanoma cells against whitening sources using mouse melanoma cells. There is a way to select. The former has the advantage of being simple and saves time and cost, but has the disadvantage that only tyrosinase inhibitors can be selected, and the latter can more comprehensively select whitening agents but has the disadvantage of costly, time and effort. .

티로시나제 효소의 활성을 억제시키면 멜라닌 색소의 생성을 억제할 수 있다는 점에 착안하여 종래의 화장품 분야에서는 미백성분으로서 히드로퀴논, 트레티노인, 코지산, 알부틴, 아스코르빈산, 글루타치온등을 티로시나제의 활성저해물질로 이용하는 방법이 이용되어 왔다. 그러나 상기 성분들을 사용하여 화장품을 제조하는 경우 그 제조과정 또는 제품보관중에 빛과의 반응에 의해 산화되어 화장품의 색이 변색되는 등의 단점이 있었다. 따라서 산화방지제, UV흡수제, 금속킬레이트제등의 첨가제를 첨가하여 이러한 변색을 줄이고자 하였다. 그러나 이러한 첨가제를 다량 사용하는 경우 피부를 자극하는등 피부안정성에 문제점이 있고, 목적하는 만큼의 충분한 미백효과를 얻을 수 없다는 단점이 있었다.In view of the fact that inhibiting the activity of tyrosinase enzymes can inhibit the production of melanin pigments, in the conventional cosmetics field, hydroquinone, tretinoin, kojic acid, arbutin, ascorbic acid, glutathione, etc. as a whitening ingredient are used as inhibitors of tyrosinase activity. The method of use has been used. However, when the cosmetics are manufactured using the above components, there are disadvantages such as discoloration due to oxidation by reaction with light during the manufacturing process or product storage. Therefore, additives such as antioxidants, UV absorbers, and metal chelating agents were added to reduce such discoloration. However, when a large amount of such additives are used, there is a problem in skin stability, such as irritating the skin, and there is a disadvantage in that sufficient whitening effects cannot be obtained as desired.

따라서 종래의 미백제에 비해 소량의 첨가제를 사용하면서도 탁월한 미백효과를 나타내며, 피부에 자극 등의 부작용이 없는 미백제를 개발하기 위해 많은 연구가 있었다.Therefore, while using a small amount of additives compared to the conventional whitening agent has an excellent whitening effect, there have been many studies to develop a whitening agent without side effects such as irritation to the skin.

본 발명자는 종래의 미백물질들이 갖는 문제점을 해결하고 보다 우수한 미백효과를 발휘하는 원료를 찾기 위해 천연물 중에서 과색소 침착예방에 유효한 물질들을 검색한 결과 죽내피 추출물이 티로시나제의 저해물질일뿐만 아니라 멜라닌 색소의 생성을 억제한다는 것을 발견하고 본 발명을 완성하게 되었다.The present inventors have searched for substances effective in preventing hyperpigmentation among natural products to solve the problems of conventional whitening materials and to find raw materials exhibiting better whitening effects. The present invention has been accomplished by finding that it inhibits the formation of.

대나무는 죽순대(반죽)라고도 하며, 중국이 원산지로 주로 남부지방에서 자생하고 있는 상록성 귀화식물이다. 대나무는 식용, 관상용, 공업용으로 사용되고 있으며, 한방과 민간에서는 대나무의 줄기, 잎 또는 죽순을 구토(嘔吐), 소염(消炎), 경간(驚癎), 주독(酒毒), 유산(流産), 익기(益氣), 객토혈(喀吐血), 금창(金瘡), 보약(補藥), 파상풍(破傷風), 발한(發汗), 진통(鎭痛), 중풍(中風)등의 약재로 사용하고 있다.Bamboo is also known as bamboo sundae (dough) and is an evergreen naturalized plant native to China and native to the south. Bamboo is used for edible, ornamental, and industrial purposes. In Chinese medicine and in private, bamboo stalks, leaves, or bamboo shoots are vomited, anti-inflammatory, spans, poisons, lactic acid, It is used for medicines such as ripening, hemolithiasis, gold spear, remedy, tetanus, sweating, pain, and stroke. .

본 발명에서 사용되는 죽내피란 대나무의 내부면에 있는 하얀 피막을 말하는 것으로, 대나무를 쪼갠 후 피막을 박피하여 사용한다. 죽내피는 대나무의 녹색외피인 제1층피와 그 내층의 하얀 제2층피와 같이 여러 가지 약효가 있으며 미백효과가 뛰어난 것으로 실험결과 밝혀졌다. 본 발명은 상기와 같은 죽내피를 미백화장료의 원료로서 유연화장수(스킨), 영양화장수(로션), 영양크림, 맛사지크림, 에센스 또는 팩등에 적용한 것이다.Bamboo skin used in the present invention refers to a white film on the inner surface of the bamboo, it is used to peel the film after splitting the bamboo. Juknapi has the same effect as the green skin of bamboo, the first layer of skin and the white layer of white layer on its inner layer. The present invention is applied to the above-mentioned bamboo endothelium as a raw material of the whitening cosmetics, such as supple cosmetic water (skin), nutrient cosmetics (lotion), nutrition cream, massage cream, essence or pack.

본 발명의 목적은 동량의 미백원료를 사용함에도 불구하고, 종래의 미백제에 비해 뛰어난 미백효과를 가지며 피부자극등의 부작용이 없는 미백화장료를 제공하는 것에 있다.It is an object of the present invention to provide a whitening cosmetic which has excellent whitening effect and no side effect such as skin irritation compared to the conventional whitening agent, despite the use of the same amount of whitening raw material.

도 1은 티로시나제의 활성저해율을 나타낸 그래프1 is a graph showing the activity inhibition rate of tyrosinase

도 2는 멜라닌 색소의 량을 나타낸 그래프2 is a graph showing the amount of melanin pigment

본 발명에 의한 미백화장료는 화장료 전체 중량을 기준으로 건조 죽내피가 0.0001∼5%, 바람직하게는 0.001∼3% 함유한다.The whitening cosmetics according to the present invention contains 0.0001 to 5% of dried bamboo flakes, preferably 0.001 to 3%, based on the total weight of the cosmetic.

본 발명을 보다 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

도 1은 티로시나제의 활성을 억제하는 정도를 그래프로 나타낸 것으로, 티로시나제의 활성을 50% 억제하는데 필요한 시료의 양을 표준편차로 표시한 것이다.1 is a graph showing the degree of inhibiting the activity of tyrosinase, a graph showing the amount of sample required to inhibit the activity of tyrosinase by standard deviation.

도 2는 실험세포에 포함된 본래의 멜라닌 양과 각각의 시료를 사용하여 배양한 후 증가된 멜라닌 양을 합산한 멜라닌 총량을 그래프로 나타낸 것으로, 각각의 시료를 사용하는 경우의 멜라닌의 총량을 표준편차로 나타낸 것이다.2 is a graph showing the total amount of melanin added to the original melanin contained in the experimental cells and the increased melanin amount after culturing with each sample, the standard deviation of the total amount of melanin when each sample is used It is represented as.

대나무의 속내피는 주로 죽세공품으로 사용되는 제2층피를 생산하는 공정에서 한약재로 사용되는 제1층피인 죽여(竹茹)와 더불어 부산물로서 얻어진다. 수득된 죽내피를 건조하여 잘게 분쇄한 후, 용매로서 에탄올 또는 메탄올과 물을 8 : 2로 혼합한 용액, 혹은 에탄올 또는 메탄올 단독으로 추출한다. 죽내피 추출물은 건조 죽내피를 15∼37℃에서 1∼15일 동안 추출용매에 침적시킴으로써 수득된다. 이렇게 하여 추출한 죽내피 추출물을 냉각콘덴서가 구비된 증류장치를 이용하여 증발되어 나오는 용매를 회수하면서 완전히 감압농축한 후 건조시키고, 건조 죽내피 0.0001∼5%, 바람직하게는 0.001∼3%를 미백화장료에 첨가한다.The inner endothelium of bamboo is obtained as a by-product along with the first layer of blood used as a medicinal herb in the process of producing the second layer of blood used mainly for bamboo work. The obtained bamboo endothelium is dried and finely pulverized, and then extracted with ethanol or methanol and a solution of 8: 2 as a solvent, or ethanol or methanol alone. The bamboo bark extract is obtained by immersing the dry bamboo bark in the extraction solvent at 15-37 ° C. for 1-15 days. The bamboo shoots extracted in this way were concentrated under reduced pressure completely while recovering the solvent evaporated using a distillation apparatus equipped with a cooling capacitor, and then dried. The dried bamboo shoots were 0.0001-5%, and preferably 0.001-3% whitening cosmetic. Add to

본 발명을 하기의 실시예, 실험예 및 처방예들을 들어 설명하지만, 이에 한정되는 것은 아니며, 본 발명의 사상과 범위 내에서 다양한 실시예, 실험예 및 처방예의 변화가 가능하다.The present invention will be described with reference to the following Examples, Experimental Examples, and Prescription Examples, but is not limited thereto, and various changes of Examples, Experimental Examples, and Prescription Examples are possible within the spirit and scope of the present invention.

(실시예)(Example)

실시예 1Example 1

대나무의 속내피 100g을 건조시켜 잘게 분쇄한 후, 80% 메탄올 3ℓ에 넣고 15∼37℃에서 14일간 추출하였다. 그 추출물을 300메시 여과포로 여과하고 5∼15℃에서 5일간 방치하여 숙성시킨 후, 여과지로 여과하였다. 이 추출물을 냉각콘덴서가 구비된 증류장치에서 70℃로 감압농축하여 건조 죽내피추출물 1.07g을 얻었다.100 g of the inner endothelium of bamboo was dried and finely pulverized, and then put in 3 L of 80% methanol and extracted at 15-37 ° C. for 14 days. The extract was filtered through a 300 mesh filter cloth, left to mature for 5 days at 5 to 15 ° C, and then filtered through a filter paper. The extract was concentrated under reduced pressure at 70 ° C. in a distillation apparatus equipped with a cooling capacitor to obtain 1.07 g of dried dead skin extract.

실시예 2Example 2

대나무의 속내피 100g을 건조시켜 잘게 분쇄한 후, 80% 에탄올 3ℓ에 넣고 15∼37℃에서 14일간 추출하였다. 그 추출물을 300메시 여과포로 여과하고 5∼15℃에서 5일간 방치하여 숙성시킨 후, 여과지로 여과하였다. 이 추출물을 냉각콘덴서가 구비된 증류장치에서 70℃로 감압농축하여 건조 죽내피추출물 1.93g을 얻었다.100 g of bamboo endothelium was dried and finely pulverized, and then placed in 3 l of 80% ethanol and extracted at 15-37 ° C. for 14 days. The extract was filtered through a 300 mesh filter cloth, left to mature for 5 days at 5 to 15 ° C, and then filtered through a filter paper. The extract was concentrated under reduced pressure at 70 ° C. in a distillation apparatus equipped with a cooling capacitor to obtain 1.93 g of dried bamboo extract.

(실험예)Experimental Example

실험예 1Experimental Example 1

실시예 1에서 수득된 건조 죽내피 추출물과 알부틴에 대하여 티로시나제 저해효과를 측정하였다. 티로시나아제는 감자나 버섯으로부터 정제되는 효소로서, 본 실험에서는 버섯 류로부터 추출한 시그마(Sigma)사의 것을 사용하였다.Tyrosinase inhibitory effect was measured on the dried bamboo endothelium extract obtained in Example 1 and arbutin. Tyrosinase is an enzyme purified from potatoes and mushrooms. In this experiment, Sigma company extracted from mushrooms was used.

먼저 기질인 티로신을 인산나트륨 완충용액(0.1M, pH6.8)에 용해시켜 0.3㎎/㎖의 농도를 갖는 용액으로 만들고, 그 용액을 334㎕를 취해 시험관에 넣은 후, 여기에 다시 인산나트륨 완충용액(0.1M, pH6.8)을 576㎕를 첨가하였다. 실시예 1의 건조 죽내피추출물을 메탄올에 용해시켜 10㎎/㎖으로 한 후, 메탄올을 사용하여 각각 5, 1.5, 1㎎/㎖, 500, 150, 100㎍/㎖로 희석시켜 실험군으로 하였다. 이 희석된 추출물 시료들을 각각 70㎕씩 취해 상기 시험관내의 용액에 첨가하고 37℃ 항온조에서 10분 동안 반응시켰다.First, the substrate tyrosine was dissolved in sodium phosphate buffer (0.1M, pH6.8) to make a solution having a concentration of 0.3 mg / ml, and the solution was taken in a test tube with 334 µl, and then again buffered with sodium phosphate 576 μl of solution (0.1M, pH6.8) was added. The dried bamboo bleed extract of Example 1 was dissolved in methanol to 10 mg / ml, and then diluted to 5, 1.5, 1 mg / ml, 500, 150, and 100 µg / ml using methanol to make an experimental group. 70 μl of each of these diluted extract samples was added to the in vitro solution and allowed to react for 10 minutes in a 37 ° C. thermostat.

대조군은 상기 죽내피 추출물 대신에 메탄올 70㎕를 넣었다. 실험군 및 대조군의 반응용액에 1700유니트/㎖의 티로시나제 용액 20㎕씩 넣어 전체 부피가 1㎖가 되게 하고, 다시 37℃ 항온조에서 30분 동안 반응시켰다. 이 반응용액이 들어 있는 시험관을 얼음물 속에 넣어 급냉시켜 티로시나제의 활성을 중지시킨 후, 광전분광분석계로 파장 470nm에서의 흡광도를 측정하였다.As a control, 70 μl of methanol was added instead of the endothelial extract. 20 µl of 1700 unit / ml tyrosinase solution was added to the reaction solution of the experimental group and the control group so that the total volume was 1 ml, and the reaction was continued for 30 minutes in a 37 ° C thermostat. The test tube containing the reaction solution was placed in iced water and quenched to stop tyrosinase activity, and then absorbance at 470 nm was measured with a photospectrometer.

실험군의 블랭크(blank)는 티로시나제 용액을 제외한 반응물, 즉 티로신, 죽내피 추출물 및 인산나트륨 완충용액으로 된 반응물이며, 대조군의 블랭크는 실험군의 블랭크에서 죽내피 추출물 대신에 메탄올을 첨가한 것으로 하였다.The blank of the experimental group was the reactant except the tyrosinase solution, that is, the tyrosine, the bamboo endothelium extract and the sodium phosphate buffer, and the blank of the control group was added methanol instead of the bamboo endothelium extract in the blank of the experimental group.

알부틴에 대한 티로시나제의 활성 저해효과를 측정하는 경우는, 알부틴을 인산나트륨 용액에 용해시켜 농도 10㎎/㎖로 한 후, 다시 인산나트륨 완충용액을 사용하여 5, 1.5, 1㎎/㎖, 500, 150, 100㎍/㎖로 희석하여 실험군으로 하였다. 알부틴의 실험군의 블랭크는 티로시나제를 제외한 반응물, 즉 티로신, 알부틴용액, 인산나트륨 완충용액으로 이루어진 반응물이다. 알부틴의 대조군은 알부틴용액 대신에 인산나트륨 완충용액을 넣은 것이고, 알부틴 대조군의 블랭크는 티로시나제용액을 제외한 반응물, 즉 티로신, 인산나트륨 완충용액을 넣은 것으로 하였다. 이상의 내용을 정리한 것을 표 1에 나타낸다.When measuring the inhibitory effect of tyrosinase activity on arbutin, arbutin was dissolved in sodium phosphate solution to a concentration of 10 mg / ml, and then again using sodium phosphate buffer solution, 5, 1.5, 1 mg / ml, 500, It diluted to 150 and 100 microgram / ml, and used it as an experimental group. The blank of the experimental group of arbutin is the reactant excluding tyrosinase, ie tyrosine, arbutin solution, sodium phosphate buffer solution. The control group of arbutin was a sodium phosphate buffer solution instead of the arbutin solution, and the blank of the arbutin control group was a reaction product except tyrosinase solution, that is, tyrosine and sodium phosphate buffer solution. Table 1 summarizes the above contents.

죽내피 추출물 및 알부틴에 대한 티로시나제의 저해율은 하기의 식을 구하였다. 그 실험결과를 표 2에 나타낸다.Inhibition rate of tyrosinase against bamboo endothelium extract and arbutin was obtained by the following equation. The experimental results are shown in Table 2.

A: 대조군의 흡광도 B: 대조군의 블랭크 흡광도A: absorbance of the control group B: blank absorbance of the control group

C: 실험군의 흡광도 D: 실험군의 블랭크 흡광도C: absorbance of the experimental group D: blank absorbance of the experimental group

사용물질Material used 실험군Experimental group 실험군의 블랭크Blank of Experimental Group 대조군Control 대조군의 블랭크Blank of Control 티로신(0.3㎎/㎖)Tyrosine (0.3 mg / ml) 334㎕334 μl 334㎕334 μl 334㎕334 μl 334㎕334 μl 인산나트륨완충용액(0.1M, pH6.8)Sodium Phosphate Buffer Solution (0.1M, pH6.8) 576㎕576 μl 596㎕596 μl 576㎕576 μl 596㎕596 μl 시료sample 70㎕70 μl 70㎕70 μl 70㎕70 μl 70㎕70 μl 티로시나제용액 (1700units/㎖)Tyrosinase solution (1700 units / ml) 20㎕20 μl -- 20㎕20 μl -- 주) 총 부피 1㎖Note) Total volume 1 ml

시료sample 티로시나제 활성을 50% 억제하는 시료의 농도(IC 50: ㎍/㎖)Sample concentration that inhibits tyrosinase activity by 50% (IC 50: μg / ml) 죽내피추출물Bamboo Blood Extract 242.30 ± 93.15242.30 ± 93.15 알부틴Arbutin 722.23 ± 348.77722.23 ± 348.77 주) 상기의 수치는 평균 ± 표준편차로 나타낸 것임Note) The above figures are expressed as mean ± standard deviation.

상기 표 2에 나타난 바와 같이, 죽내피 추출물은 알부틴 보다 티로시나제의 활성을 억제하는 능력이 약 3배 정도 높다는 것을 알 수 있다.As shown in Table 2, it can be seen that the porridge extract has about 3 times higher ability to inhibit tyrosinase activity than arbutin.

실험예 2Experimental Example 2

상기 죽내피 추출물에 대한 멜라닌 색소의 생성 저해효과를 측정하였다.The inhibitory effect of the production of melanin pigment on the bamboo endothelium extract was measured.

쥐의 흑색종 세포로부터 유도된 색소형성 세포를 표준방법으로 배양물 중에 성장시켰다. 본 실험에서는 B-16세포(ATCC사, 미국)의 세포주를 사용하였으나, 다른 세포주 또는 사람의 멜라닌세포를 사용할 수 있다.Pigmented cells derived from mouse melanoma cells were grown in culture by standard methods. In this experiment, cell lines of B-16 cells (ATCC, USA) were used, but other cell lines or human melanocytes can be used.

흑색종 세포를 10% 소의 태아혈청, 1% 항생제, 10-7M의 α-MSH(멜라닌세포 자극호르몬, Sigma사 제조)가 들어 있는 RPMI(Gibco사)의 세포배양 배지에 공급하여 약 1/3 정도의 콘플루언스(confluence)로 성장시켰다. 이어서 각각의 시료, 예를 들어 실시예 1에서 수득된 건조 죽내피추출물, 코지산, 알부틴 및 아스코르빈산을 50㎍/㎖의 농도로 배양배지에 용해하고, 계속해서 시료가 들어 있는 용액을 흑색종 세포에 가한 후 2일 이상 배양하였다. 대조군은 시료가 들어 있지 않은 배양배지를 넣어 주었다. 배양후 세포들을 트립신-EDTA(Gibco사)로 처리하여 시험관에 모은 후 세포들의 수를 세고, 4,000,000 세포당 1㎖의 1N 수산화용액을 첨가하여 멜라닌을 녹여 낸 후 470nm에서의 흡광도를 측정하여 분석하였다. 그 실험결과를 표 3에 나타낸다.Melanoma cells were supplied to RPMI (Gibco) cell culture medium containing 10% fetal bovine serum, 1% antibiotic, and 10 -7 M α-MSH (Meline Cell Stimulating Hormone, manufactured by Sigma). It grew to about 3 confluences. Subsequently, each sample, for example, the dried bamboo extract, kojic acid, arbutin and ascorbic acid obtained in Example 1, was dissolved in the culture medium at a concentration of 50 µg / ml, and the solution containing the sample was then black. After addition to the species cells were incubated for 2 days or more. The control group was put in a culture medium containing no sample. After incubation, the cells were treated with trypsin-EDTA (Gibco Co., Ltd.), collected in a test tube, and counted. The cells were dissolved in melanin by adding 1 ml of 1N hydroxide solution per 4,000,000 cells, and the absorbance at 470 nm was measured and analyzed. . The experimental results are shown in Table 3.

시료sample 멜라닌량(㎍/㎖/4,000,000셀)Melanin amount (µg / ml / 4,000,000 cells) 억제율(%)% Inhibition 대조군Control 97.17 ± 18.8597.17 ± 18.85 -- 죽내피추출물Bamboo Blood Extract 43.79 ± 15.5043.79 ± 15.50 54.9%54.9% 알부틴Arbutin 51.79 ± 8.9051.79 ± 8.90 46.7%46.7% 코지산Kojisan 49.83 ± 8.2549.83 ± 8.25 48.7%48.7% 아스코르빈산Ascorbic acid 137.03 ± 41.39137.03 ± 41.39 -41.0%-41.0% 주) 상기 수치는 평균 ± 표준편차로 나타낸 것임NOTE The above figures are expressed as mean ± standard deviation.

표 3에서 알 수 있는 바와 같이, 죽내피 추출물은 대조군에 비해 B-16 흑색종 세포의 멜라닌양을 억제할 수 있으며, 같은 양의 알부틴이나 코지산을 사용하는 경우 보다 멜라닌 생성양이 적음을 알 수 있다.As can be seen in Table 3, the bamboo endothelium extract can inhibit the amount of melanin in B-16 melanoma cells compared to the control group, and the amount of melanin produced is lower than that of the same amount of arbutin or kojic acid. Can be.

(처방예)(Prescription example)

처방예 1: 영양크림Prescription Example 1: Nutritional Cream

하기와 같이, 실시예 2에서 수득한 죽내피 추출물을 함유한 영양크림을 통상의 방법에 따라 제조하였다.As follows, the nourishing cream containing the bamboo endosperm extract obtained in Example 2 was prepared according to a conventional method.

성분ingredient 함량(중량%)Content (% by weight) 죽내피추출물Bamboo Blood Extract 0.10.1 유동파라핀Liquid paraffin 6.06.0 스쿠알란Squalane 4.04.0 소르비탄세스퀴올레이트Sorbitan sesquioleate 0.50.5 폴리솔베이트 60Polysorbate 60 1.51.5 밀랍beeswax 10.010.0 카프필릭/카프릭트리글리세라이드Capric & Capric Triglycerides 5.05.0 농 글리세린Concentrated glycerin 6.06.0 프로필렌글리콜Propylene glycol 3.03.0 부틸렌글리콜Butylene glycol 2.02.0 트리에탄올아민Triethanolamine 0.20.2 방부제antiseptic 미량a very small amount 색소Pigment 미량a very small amount 향료Spices 미량a very small amount 정제수Purified water 잔부Balance

처방예 2: 영양화장수Prescription Example 2: Nutritional Cosmetics

하기와 같이, 실시예 2에서 수득한 죽내피 추출물을 함유한 영양화장수(로션)을 통상의 방법에 따라 제조하였다.As follows, the nutrient lotion (lotion) containing the bamboo endosperm extract obtained in Example 2 was prepared according to a conventional method.

성분ingredient 함량(중량%)Content (% by weight) 죽내피추출물Bamboo Blood Extract 0.10.1 세탄올Cetanol 1.01.0 스테아릴알코올Stearyl alcohol 1.01.0 글리세린모노스테아레이트Glycerin Monostearate 3.03.0 소르비탄모노스테아레이트Sorbitan monostearate 1.01.0 폴리옥시에틸렌소르비탄 모노올레이트Polyoxyethylene sorbitan monooleate 2.02.0 바셀린vaseline 2.02.0 유동파라핀Liquid paraffin 6.06.0 스쿠알란Squalane 5.05.0 옥틸도데실미리스테이트Octyldodecyl Myristate 5.05.0 글리세린glycerin 5.05.0 1,3-부틸렌글리콜1,3-butylene glycol 5.05.0 카르복시비닐폴리머Carboxy Vinyl Polymer 0.30.3 트리에탄올아민Triethanolamine 0.30.3 방부제antiseptic 미량a very small amount 색소Pigment 미량a very small amount 향료Spices 미량a very small amount 정제수Purified water 잔부Balance

처방예 3: 유연화장수Formulation Example 3: Softening Cosmetics

하기와 같이, 실시예 2에서 수득한 죽내피 추출물을 함유한 유연화장수(스킨)을 통상의 방법에 따라 제조하였다As described below, the softening water (skin) containing the bamboo endosperm extract obtained in Example 2 was prepared according to a conventional method.

성분ingredient 함량(중량%)Content (% by weight) 죽내피추출물Bamboo Blood Extract 0.10.1 농 글리세린Concentrated glycerin 2.02.0 프로필렌글리콜Propylene glycol 3.03.0 부틸렌글리콜Butylene glycol 2.02.0 에탄올ethanol 10.010.0 카르복시비닐폴리머Carboxy Vinyl Polymer 0.10.1 트리에탄올아민Triethanolamine 0.10.1 방부제antiseptic 미량a very small amount 색소Pigment 미량a very small amount 향료Spices 미량a very small amount 정제수Purified water 잔부Balance

처방예 4: 에센스Prescription 4: Essence

하기와 같이, 실시예 2에서 수득한 죽내피 추출물을 함유한 에센스를 통상의 방법에 따라 제조하였다.As follows, the essence containing the bamboo endothelium extract obtained in Example 2 was prepared according to a conventional method.

성분ingredient 함량(중량%)Content (% by weight) 죽내피추출물Bamboo Blood Extract 0.10.1 플로필렌글리콜Pluylene glycol 5.05.0 글리세린glycerin 10.010.0 1,3-부틸렌글리콜1,3-butylene glycol 10.010.0 폴리에틸렌글리콜 1500Polyethylene Glycol 1500 5.05.0 카르복시비닐폴리머Carboxy Vinyl Polymer 0.50.5 히드록시에틸셀룰로오스Hydroxyethyl cellulose 0.50.5 트리에탄올아민Triethanolamine 0.50.5 에탄올ethanol 5.05.0 폴리옥시에틸렌노닐페닐에테르Polyoxyethylene nonylphenyl ether 0.70.7 방부제antiseptic 미량a very small amount 색소Pigment 미량a very small amount 향료Spices 미량a very small amount 정제수Purified water 잔부Balance

처방예 5: 맛사지크림Prescription 5: Massage cream

하기와 같이, 실시예 2에서 수득한 죽내피 추출물을 함유한 맛사지크림을 통상의 방법에 따라 제조하였다.As follows, the massage cream containing the bamboo endosperm extract obtained in Example 2 was prepared according to a conventional method.

성분ingredient 함량(중량%)Content (% by weight) 죽내피추출물Bamboo Blood Extract 0.10.1 유동파라핀Liquid paraffin 40.040.0 스쿠알란Squalane 5.05.0 소르비탄세스퀴올레이트Sorbitan sesquioleate 0.80.8 폴리솔베이트 60Polysorbate 60 1.51.5 밀랍beeswax 10.010.0 카프필릭/카프릭트리글리세라이드Capric & Capric Triglycerides 4.04.0 농 글리세린Concentrated glycerin 6.06.0 프로필렌글리콜Propylene glycol 2.02.0 부틸렌글리콜Butylene glycol 4.04.0 트리에탄올아민Triethanolamine 0.20.2 방부제antiseptic 미량a very small amount 색소Pigment 미량a very small amount 향료Spices 미량a very small amount 정제수Purified water 잔부Balance

처방예 6: 팩Prescription 6: Pack

하기와 같이, 실시예 2에서 수득한 죽내피 추출물을 함유한 팩을 통상의 방법에 따라 제조하였다.As follows, a pack containing the bamboo endosperm extract obtained in Example 2 was prepared according to a conventional method.

성분ingredient 함량(중량%)Content (% by weight) 죽내피추출물Bamboo Blood Extract 0.10.1 알란토인Allantoin 0.20.2 에탄올ethanol 5.05.0 노닐페닐에테르Nonylphenyl Ether 0.30.3 나트륨카르복시메틸셀룰로오스Sodium Carboxymethyl Cellulose 0.20.2 폴리비닐알코올Polyvinyl alcohol 13.013.0 방부제antiseptic 미량a very small amount 색소Pigment 미량a very small amount 향료Spices 미량a very small amount 정제수Purified water 잔부Balance

상기의 시험결과로부터 본 발명의 죽내피 추출물은 종래의 알부틴 또는 코지산과 비해 멜라닌 색소형성의 억제작용이 우수하며, 이에 따라 피부미백효과가 우수하다는 것을 알 수 있다.From the above test results, the bamboo endothelium extract of the present invention is superior to the conventional arbutin or koji acid melanin pigmentation inhibitory effect, it can be seen that the skin whitening effect is excellent.

Claims (5)

죽내피 추출물을 함유한 미백화장료.Whitening cosmetics containing bamboo extract. 청구항 1에 있어서, 죽내피 추출물을 화장료 전체에 대해 건조 중량기준으로 0.0001∼5% 함유하는 미백화장료.The whitening cosmetic of Claim 1 which contains 0.0001 to 5% of bamboo endosperm extract on dry weight basis with respect to the whole cosmetics. 청구항 1에 있어서, 추출용매는 에탄올 또는 메탄올인 미백화장료.The whitening cosmetic of claim 1, wherein the extraction solvent is ethanol or methanol. 청구항 1에 있어서, 추출용매는 에탄올 또는 메탄올과, 물과의 혼합용매인 미백화장료.The whitening cosmetic according to claim 1, wherein the extraction solvent is a mixed solvent of ethanol or methanol and water. 청구항 3 또는 4에 있어서, 죽내피 추출물은 죽내피를 15∼37℃하에 상기 용매에 1∼15일 동안 침적하여 추출하는 방법에 의해 수득되는 것인 미백화장료.The whitening cosmetic according to claim 3 or 4, wherein the bamboo bark extract is obtained by extracting bamboo bark by immersing the bark bark in the solvent at 15 to 37 ° C for 1 to 15 days.
KR10-1998-0027529A 1998-07-08 1998-07-08 Whitening cosmetics containing bamboo extract KR100357402B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-1998-0027529A KR100357402B1 (en) 1998-07-08 1998-07-08 Whitening cosmetics containing bamboo extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-1998-0027529A KR100357402B1 (en) 1998-07-08 1998-07-08 Whitening cosmetics containing bamboo extract

Publications (2)

Publication Number Publication Date
KR20000007943A true KR20000007943A (en) 2000-02-07
KR100357402B1 KR100357402B1 (en) 2003-03-03

Family

ID=19543513

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0027529A KR100357402B1 (en) 1998-07-08 1998-07-08 Whitening cosmetics containing bamboo extract

Country Status (1)

Country Link
KR (1) KR100357402B1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100439868B1 (en) * 2001-04-18 2004-07-12 주식회사 태평양 A compositions for skin external application containing the sap of bamboo
KR100454115B1 (en) * 2001-02-28 2004-10-26 애경산업(주) Method for Separating 1,2-di-o-feruloylglycerol and Cosmetic Composition Containing the Same and its Use
KR100639408B1 (en) 2004-09-21 2006-10-30 전남대학교산학협력단 Cosmetic composition comprising the extract of Bambusae Folium showing inhibitory effect and whitening effect on UV-induced skin damage
KR100972466B1 (en) * 2009-07-02 2010-07-26 (주)화순테마랜드 Method for manufacturing bambuase caulis in liquamen powder
KR20160000061U (en) 2014-06-27 2016-01-06 한상우 Lighting equipment for maintenance of car
CN108309920A (en) * 2018-05-15 2018-07-24 贝德氏(上海)健康科技股份有限公司 A kind of skin care item for repairing skin barrier

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101782488B1 (en) * 2015-05-19 2017-09-28 주식회사 스템랩 Method for Inducing Oligodendrocyte Progenitor Cells from Human Somatic Cells Introduced with Oct4 Through Direct Reprogramming

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454115B1 (en) * 2001-02-28 2004-10-26 애경산업(주) Method for Separating 1,2-di-o-feruloylglycerol and Cosmetic Composition Containing the Same and its Use
KR100439868B1 (en) * 2001-04-18 2004-07-12 주식회사 태평양 A compositions for skin external application containing the sap of bamboo
KR100639408B1 (en) 2004-09-21 2006-10-30 전남대학교산학협력단 Cosmetic composition comprising the extract of Bambusae Folium showing inhibitory effect and whitening effect on UV-induced skin damage
KR100972466B1 (en) * 2009-07-02 2010-07-26 (주)화순테마랜드 Method for manufacturing bambuase caulis in liquamen powder
KR20160000061U (en) 2014-06-27 2016-01-06 한상우 Lighting equipment for maintenance of car
CN108309920A (en) * 2018-05-15 2018-07-24 贝德氏(上海)健康科技股份有限公司 A kind of skin care item for repairing skin barrier

Also Published As

Publication number Publication date
KR100357402B1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
KR101971837B1 (en) Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component
KR102158780B1 (en) Composition for improving skin comprising natural material extract
KR20200138870A (en) Composition for preventing or improving skin aging comprising an extract of rhodiola sachalinesis fermented by bovista plumbea
KR100357402B1 (en) Whitening cosmetics containing bamboo extract
KR102236071B1 (en) Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater
US20170196797A1 (en) Composition containing glycine gracilis oil
KR101071414B1 (en) Composition for Whitening Containing Extract of Annona muricata as an active ingredient
KR20190063549A (en) Cosmetic Composition Comprising Bamboo Fermented Extract
KR102632084B1 (en) Cosmetic composition for anti-oxidation, skin whitening, and improving of skin wrinkle containing Sanguisorba officinalis extract
KR100496850B1 (en) The Skin Lightening Cosmetic Composition Containing Extract Of Gardenia
KR102471009B1 (en) Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles
KR20140089305A (en) Composition for improving skin whitening or skin wrinkle comprising extracts of Quercus salicina Blume
JP2000319122A (en) Cell proliferation promoting cosmetic
KR20040075139A (en) Cosmetic Composition For Skin Whitening Comprising Submerged-Liquid Culture Of Paecilomyces japonica Mycelia with a Mixed Juice of Grape and Cucumber
KR100416400B1 (en) Composition containing extracts from dried roots of Trichosantes kirilowii maxim for external application and skin-whitening and process for preparation thereof
KR20100042090A (en) Composition for whitening containing extract of jasminum grandiflorum
KR20210144725A (en) Anti-aging, antioxidant, anti-inflammatory and whitening agents, and cosmetics
KR20090111679A (en) Whitening cosmetic composition including the extract of Astragali Radix
TW202027717A (en) Fermentation product of punica granatum and use of the fermentation product of punica granatum for inhibiting melanogenesis and whitening
KR102628844B1 (en) Cosmetic composition for anti-oxidation, skin whitening and anti-wrinkle containing a mixed fermentation extracts of Wisteria floribunda flowers, Aralia elata flowers, Camellia japonica leafs and Camellia japonica flowers as effective component
KR20200038114A (en) Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom
CN113631227B (en) Anti-aging agent, antioxidant, anti-inflammatory agent, whitening agent, and cosmetic
KR102650192B1 (en) Cosmetic composition comprising snowberry flesh and preparation method thereof
KR102393811B1 (en) Composition comprising for whitening of skin containing fermented solution
KR102163882B1 (en) Composition for skin whitening containing Panax ginseng extract and Green tea extract

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20011026

Effective date: 20020829

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121008

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131007

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20141006

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20151007

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20161005

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20171010

Year of fee payment: 16

EXPY Expiration of term